EUROPEAN COOPERATIVE STUDY OF PRIMARY SYSTEMIC THERAPY IN WOMEN WITH OPERABLE BREAST CANCER AND T < 2 CM

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004957-24-IT

Enrollment

160

Registered

2005-07-12

Start date

2005-04-27

Completion date

Unknown

Last updated

2013-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary systemic therapy in operable breast cancer &lt

Interventions

Trade Name: XELODA*120CPR RIV 500MG Pharmaceutical Form: Coated tablet INN or Proposed INN: Capecitabine Concentration unit: mg milligram(s) Concentration number: 500- Trade Name: ADRIBLASTINA*EV FL

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Germany, Italy, Spain

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026

EUROPEAN COOPERATIVE STUDY OF PRIMARY SYSTEMIC THERAPY IN WOMEN WITH OPERABLE BREAST CANCER AND T &lt; 2 CM